An interventional study of Sunrise in Sleep Apnea Syndrome, Obstructive, sponsored by University Hospital, Grenoble. Recruiting at 1 site in France. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-17.
Sponsored by University Hospital, Grenoble · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Sleep Apnea, Obstructive by University Hospital, Grenoble — 6 open to participants now, 6 under way, none of them phase 3. Sleep Apnea, Obstructive · University Hospital, Grenoble.
Among the 48 studies in Sleep Apnea, Obstructive by University Hospital, Grenoble, this one is the 7th largest by planned enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2026, is one of 25 with no phase, and was the 47th registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →6 of the 48 studies in Sleep Apnea, Obstructive by University Hospital, Grenoble are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Grenoble · Sites in France
Ages 18–75
University Hospital, Grenoble · Sites in France
Ages 18+
University Hospital, Grenoble · Sites in France
Ages 18–75
University Hospital, Grenoble · Sites in France
Ages 18–80
University Hospital, Grenoble · Sites in France
Ages 18–85
By country, each count listing its studies:
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 105 is above the median of 52 across 1,476 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 54 across the 32 interventional studies, 158 across the 16 observational. Of the 29 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Grenoble is the lead sponsor of 838 studies on the registry; 208 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 48 studies in Sleep Apnea, Obstructive by University Hospital, Grenoble, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to determine whether treatment-adjustment decisions based on one night of home monitoring with the Sunrise device are comparable to decisions based on one night of in-laboratory polysomnography (PSG) in adults with obstructive sleep apnea (OSA) who remain insufficiently controlled with continuous positive airway pressure (CPAP) therapy.
The main questions it aims to answer are:
Participants will complete both assessment sequences in a randomized cross-over design. They will:
Obstructive sleep apnea (OSA) affects nearly one billion adults worldwide and is associated with recurrent upper-airway obstruction during sleep, leading to intermittent hypoxemia and multiple cardiometabolic and neurocognitive comorbidities. Continuous positive airway pressure (CPAP) is the standard treatment and is widely prescribed, with more than 1.8 million users in France. Despite its proven efficacy, large-scale analyses show that over 10% of treated patients continue to exhibit elevated residual apnea-hypopnea indices (AHI), a situation associated with reduced adherence and premature discontinuation of therapy.
Evaluation of CPAP effectiveness typically relies on in-laboratory polysomnography (PSG), which remains the reference method for characterizing residual respiratory events and sleep architecture. However, the need for PSG generates substantial healthcare costs, long waiting times, and unequal access to diagnostic resources.
The Sunrise device is a CE-marked medical device that records mandibular movements during sleep and uses artificial intelligence to characterize respiratory events and sleep parameters. Multiple validation studies have demonstrated strong agreement between Sunrise-derived metrics and PSG.
This randomized cross-over trial investigates whether Sunrise can be used to guide therapeutic decisions in patients with insufficiently controlled OSA under CPAP therapy, defined by a residual AHI greater than 10 events per hour. Participants are randomized to one of two sequences:
This design allows each participant to serve as their own control and enables direct comparison of treatment-adjustment decisions derived from Sunrise versus PSG. The study aims to determine whether a home-based, low-burden assessment could replace or reduce the need for in-laboratory evaluations, thereby improving access to care, reducing costs, and facilitating personalized CPAP management.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will first undergo an overnight, in-laboratory polysomnography (PSG) in the sleep center. After this in-lab recording period, they will complete an at-home sleep assessment using the Sunrise device over the predefined home recording period.
Device: Sunrise
Participants will first complete an at-home sleep assessment using the Sunrise device over the predefined home recording period. After this home recording period, they will undergo an overnight, in-laboratory polysomnography (PSG) in the sleep center.
Device: Sunrise
The Sunrise device is a single-use, mandibular movement-based sleep monitoring sensor designed to assess sleep architecture and respiratory events at home. In this study, Sunrise is evaluated as an alternative to in-laboratory polysomnography (PSG), which is considered the current gold-standard reference for sleep assessment.
Cohen's Kappa for Agreement Between Therapeutic Adjustment Decisions Based on Sunrise and Polysomnography (PSG)
Agreement between therapeutic adjustment decisions derived from Sunrise home recordings and in-lab polysomnography (PSG), quantified using Cohen's kappa coefficient. Two independent experts will provide decisions for each modality; disagreements will be resolved by consensus. The therapeutic decision is a three-category variable: No change in CPAP treatment, adjustment of CPAP pressure or change of mask, switch to servo-ventilation if residual events are predominantly central.
Time frame: Within 1 night for each modality (Sunrise home recording and in-lab PSG).
Cohen's Kappa for Agreement Between Therapeutic Adjustment Decisions Based on Three-Night Sunrise Recordings and Polysomnography (PSG)
Agreement between therapeutic adjustment decisions derived from three consecutive nights of Sunrise home recordings and in-lab polysomnography (PSG), quantified using Cohen's kappa coefficient. Two independent experts will provide decisions for each modality; disagreements will be resolved by consensus. The therapeutic decision is a three-category variable: No change in CPAP treatment, adjustment of CPAP pressure or change of mask, switch to servo-ventilation if residual events are predominantly central.
Time frame: Three consecutive home nights for Sunrise recordings and one in-lab PSG night.
Agreement Between PSG-Measured rAHI and Sunrise-Measured rAHI (One Night and Three Nights)
This outcome evaluates the concordance between the residual Apnea-Hypopnea Index (rAHI) measured by: * in-lab polysomnography (PSG) during one night (gold standard), * the Sunrise device during the first home night, * the Sunrise device across three consecutive home nights. For each modality, rAHI values will be interpreted by two independent experts, blinded to the results of the other method. In case of disagreement between the two experts for a given modality, they will meet to reach a consensus rAHI interpretation, following the same adjudication procedure as for the primary outcome. The analysis will compare rAHI obtained from PSG with rAHI obtained from Sunrise over one night and over three nights to assess the level of agreement between modalities.
Time frame: One in-lab PSG night; one or three consecutive home nights with Sunrise.
Inter-Rater Agreement Between the Two Independent Experts for Therapeutic Adjustment Decisions
For each participant and for each assessment modality (in-lab PSG, one-night Sunrise recording, and three-night Sunrise recording), the therapeutic adjustment decision will be independently provided by Expert 1 and Expert 2, each blinded to the other's evaluation. The therapeutic decision is a three-category variable: * No change in CPAP treatment, * Adjustment of CPAP pressure or change of mask, * Switch to servo-ventilation if residual events are predominantly central. This outcome measures the inter-rater agreement between the two experts for each modality, based on their initial independent decisions (before any consensus meeting).
Time frame: One in-lab PSG night; one or three consecutive home nights with Sunrise.
Plan to share: No
Started Jun 2026 (actual). Primary completion is estimated for Sep 2029, 39 months after the start.
Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 39 months is above that.
Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Grenoble →